伴有溶骨性骨转移的前列腺癌：18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描用于诊断及监测药物去势治疗的反应
Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy.
作者信息
Sharma Punit, Karunanithi Sellam, Singh Dhull Varun, Jain Sachin, Bal Chandrasekhar, Kumar Rakesh
机构信息
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Indian J Nucl Med. 2013 Jul;28(3):178-9. doi: 10.4103/0972-3919.119545.
Abstract
Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed response to medical castration therapy. While the role of (18)F-FDG PET-CT for sclerotic bone metastases in prostate cancer remains controversial, it appears to be useful for detection and response assessment of lytic prostate cancer metastases.
摘要
溶骨性骨转移在前列腺癌中较为罕见。我们在此展示一名67岁男性前列腺癌溶骨性转移患者的18氟脱氧葡萄糖（(18)F-FDG）正电子发射断层扫描计算机断层扫描（PET-CT）图像。6个月后进行的重复(18)F-FDG PET-CT显示对药物去势治疗有反应。虽然(18)F-FDG PET-CT在前列腺癌硬化性骨转移中的作用仍存在争议，但它似乎对溶骨性前列腺癌转移的检测和反应评估有用。
相似文献
1
Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy.
Indian J Nucl Med. 2013 Jul;28(3):178-9. doi: 10.4103/0972-3919.119545.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Increased Prostate Cancer Glucose Metabolism Detected by F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.
Eur Urol Focus. 2019 Nov;5(6):998-1006. doi: 10.1016/j.euf.2018.03.008. Epub 2018 Mar 30.
4
FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series.
Ann Nucl Med. 2012 Jan;26(1):86-91. doi: 10.1007/s12149-011-0538-3. Epub 2011 Sep 28.
5
Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Urol J. 2018 Sep 26;15(5):242-247. doi: 10.22037/uj.v0i0.4065.
6
Uptake of Radium-223 Dichloride and Early [F]NaF PET Response Are Driven by Baseline [F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.
Mol Imaging Biol. 2018 Jun;20(3):482-491. doi: 10.1007/s11307-017-1132-4.
7
Evaluation of Response to Therapy in a Patient with Lung Cancer: Correlation of Sclerotic Bone Lesions with F 18 FDG PET/CT and Bone Scintigraphy.
Mol Imaging Radionucl Ther. 2011 Apr;20(1):29-33. doi: 10.4274/MIRT.20.06. Epub 2011 Apr 1.
8
Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11. doi: 10.1007/s00259-002-1104-y. Epub 2003 Feb 13.
9
DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
BJU Int. 2021 Feb;127(2):254-262. doi: 10.1111/bju.15206. Epub 2020 Sep 7.
10
Positron emission tomography and bone metastases.
Semin Nucl Med. 2005 Apr;35(2):135-42. doi: 10.1053/j.semnuclmed.2004.11.005.
引用本文的文献
1
A Rare Case of Primary Hyperparathyroidism and Hypercalcemia of Malignancy Seen in a Patient With Prostate Adenocarcinoma.
Cureus. 2023 Aug 14;15(8):e43497. doi: 10.7759/cureus.43497. eCollection 2023 Aug.
2
Prostate cancer bone metastases biology and clinical management (Review).
Oncol Lett. 2023 Mar 8;25(4):163. doi: 10.3892/ol.2023.13749. eCollection 2023 Apr.
3
Osteolytic lesions: Multiple myeloma or prostate cancer?
Radiol Case Rep. 2023 Feb 2;18(4):1485-1489. doi: 10.1016/j.radcr.2023.01.054. eCollection 2023 Apr.
4
Paraneoplastic Hyperfibrinolysis: Detection of Occult Prostate Cancer with 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography.
Indian J Nucl Med. 2021 Apr-Jun;36(2):203-204. doi: 10.4103/ijnm.IJNM_195_20. Epub 2021 Jun 21.
5
Exploiting bone niches: progression of disseminated tumor cells to metastasis.
J Clin Invest. 2021 Mar 15;131(6). doi: 10.1172/JCI143764.
6
Prostate carcinoma presenting with diffuse osteolytic metastases and supraclavicular lymphadenopathy mimicking multiple myeloma.
Clin Case Rep. 2017 Dec 19;6(2):253-257. doi: 10.1002/ccr3.1336. eCollection 2018 Feb.
7
Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.
Radiol Med. 2016 Dec;121(12):905-915. doi: 10.1007/s11547-016-0675-9. Epub 2016 Aug 27.
8
F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.
Oncol Lett. 2016 Jan;11(1):316-322. doi: 10.3892/ol.2015.3903. Epub 2015 Nov 10.
本文引用的文献
1
Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Rev Esp Med Nucl. 2011 Mar-Apr;30(2):94-6. doi: 10.1016/j.remn.2010.10.008. Epub 2011 Feb 20.
2
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med. 2011 Mar;36(3):192-8. doi: 10.1097/RLU.0b013e318208f140.
3
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
J Nucl Med. 2011 Jan;52(1):81-9. doi: 10.2967/jnumed.110.077941. Epub 2010 Dec 13.
4
Glucose metabolism of human prostate cancer mouse xenografts.
Mol Imaging. 2005 Apr-Jun;4(2):91-7. doi: 10.1162/15353500200505118.
5
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Urology. 2002 Jun;59(6):913-8. doi: 10.1016/s0090-4295(02)01509-1.
6
FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.
Nucl Med Commun. 2001 Sep;22(9):963-9. doi: 10.1097/00006231-200109000-00004.
7
Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo.
Int J Cancer. 1999 Jan 18;80(2):257-64. doi: 10.1002/(sici)1097-0215(19990118)80:2<257::aid-ijc15>3.0.co;2-3.
8
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Radiology. 1996 Jun;199(3):751-6. doi: 10.1148/radiology.199.3.8638000.
9
Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast.
Clin Radiol. 1987 Jul;38(4):351-5. doi: 10.1016/s0009-9260(87)80207-6.
Zotero 插件